Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.57 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | TGM2 | P21980 | 1/20 | 0.51 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.50 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.50 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3844555 | 0.87 | LMNA (0.58) | LMNASMN1; SMN2SLC1A3SLC1A1HTT | |
| SCHEMBL863804 | 0.84 | LMNA (0.65) | LMNASMN1; SMN2SLC1A3SLC1A1HTT | |
| SCHEMBL7752769 | 0.82 | LMNA (0.67) | LMNASMN1; SMN2SLC1A3SLC1A1HTT | |
| (Benzyloxycarbonylamino)Methylphosphonic Acid SCHEMBL5586441 | 0.82 | LMNA (0.61) | LMNASMN1; SMN2HTTTGM2HSD17B10 | |
| SCHEMBL18085402 | 0.81 | SLC1A3 (0.62) | LMNASMN1; SMN2SLC1A3SLC1A1HTT | |
| SCHEMBL16269912 | 0.81 | SLC1A3 (0.62) | LMNASMN1; SMN2SLC1A3SLC1A1HTT | |
| SCHEMBL3362572 | 0.81 | HTT (0.67) | LMNASMN1; SMN2SLC1A3SLC1A1HTT | |
| SCHEMBL13055383 | 0.81 | LMNA (0.80) | LMNASMN1; SMN2SLC1A3SLC1A1HTT | |
| SCHEMBL7378562 | 0.81 | LMNA (0.65) | LMNASMN1; SMN2SLC1A3SLC1A1HTT | |
| SCHEMBL7855071 | 0.81 | ELANE (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040181078-A1 | Tetraphosphonate bicyclic trisanhydrides | PHARMASSET, LTD. | 2004-09-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040181078-A1 | Tetraphosphonate bicyclic trisanhydrides | IDH1, PPIP5K2, DHPS | LMNA 2232/4885SMN1; SMN2 3379/4885SLC1A3 2383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.